Abrdn Life Sciences Investors Plans Dividend of $0.43 (NYSE:HQL)

Abrdn Life Sciences Investors (NYSE:HQL) declared a dividend on Tuesday, May 20th, investing.com reports. Investors of record on Friday, May 23rd will be given a dividend of 0.43 per share on Monday, June 30th. This represents a dividend yield of 13.82%. The ex-dividend date of this dividend is Thursday, May 22nd.

Abrdn Life Sciences Investors Stock Up 1.1%

Abrdn Life Sciences Investors stock opened at $12.46 on Tuesday. The stock’s 50 day moving average is $12.28 and its 200 day moving average is $13.31. Abrdn Life Sciences Investors has a one year low of $10.55 and a one year high of $15.90.

Insider Buying and Selling

In other Abrdn Life Sciences Investors news, major shareholder Saba Capital Management, L.P. sold 48,623 shares of the business’s stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $12.58, for a total value of $611,677.34. Following the transaction, the insider now directly owns 3,188,405 shares of the company’s stock, valued at approximately $40,110,134.90. The trade was a 1.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 198,861 shares of company stock valued at $2,422,653 over the last ninety days. 10.06% of the stock is owned by company insiders.

Hedge Funds Weigh In On Abrdn Life Sciences Investors

A hedge fund recently raised its stake in Abrdn Life Sciences Investors stock. Royal Bank of Canada raised its holdings in Abrdn Life Sciences Investors (NYSE:HQL) by 53.3% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 73,475 shares of the company’s stock after buying an additional 25,542 shares during the quarter. Royal Bank of Canada owned 0.25% of Abrdn Life Sciences Investors worth $934,000 as of its most recent SEC filing. Institutional investors own 32.21% of the company’s stock.

About Abrdn Life Sciences Investors

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.